Clinical Oncology (Medical Treatment, Radiotherapy) and Precision Medicine

All Items

• NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial

  Jean-Matthieu L'Orphelin, Ugo Lancien , Jean-Michel Nguyen , Francisco J.S. Coronilla, Soraya Saiagh , Julie Cassecuel , Lise Boussemart, Anne Dompmartin , Brigitte Dréno

  867-877

• The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy

  Cem Onal, Ozan Cem Guler, Aysenur Elmali, Birhan Demirhan, Melek Yavuz

  858-866

• Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity

  Lucy A. van Werkhoven, Eugenio Cammareri, Mischa S. Hoogeman, Remi A. Nout, Maaike T.W. Milder, Joost J.M.E. Nuyttens

  822-832

• A dosimetric and robustness analysis of proton arc therapy with early energy layer and spot assignment for lung cancer versus conventional intensity modulated proton therapy

  Macarena S. Chocan, Sophie Wuyckens, Damien Dasnoy, Dario Di Perri, Elena Borderias Villarruel, Erik Engwall, John A. Lee, Ana M. Barragan-Montero, Edmond Sterpin

  805-815

• Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas

  Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim

  798-804

• Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

  Kerstin Gunnarsson, Louise Mövik, Niclas Pettersson, Anna Bäck, Jan Nyman, Andreas Hallqvist

  791-797

• Classic Kaposi sarcoma: Diagnostics, treatment modalities, and genetic implications – A review of the literature

  Ron Batash, Alberto Crimí, Riad Kassem, Murad Asali, Ishay Ostfeld, Carlo Biz, Pietro Ruggieri, Moshe Schaffer

  783-790

• Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study

  Mari Lahelma, Heini Rauhamaa, Riikka-Leena Leskelä, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen

  763-771

• Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study

  Mari Lahelma, Heini Rauhamaa, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen

  772-782

• Intensity-modulated proton radiotherapy spares musculoskeletal structures in regional nodal irradiation for breast cancer: a dosimetric comparison

  Jessica F. Burlile, Satomi Shiraishi, Heather J. Gunn, Jennifer L. Bradt, Haley M. Kroeplin, Karen G. Lang, Jenna K. Cimmiyotti, Nicolas Depauw, Connie Y. Chang, Kevin M. Brom, Cassandra L. Sonnicksen, Anhmai Vu, Rachel B. Jimenez, Kimberly S. Corbin

  755-762
• 

  Home self-testing of complete blood counts in patients with breast cancer during chemotherapy: A proof-of-concept cohort study in e-oncology

  Lennart Friis-Hansen, Pippi Jonassen Bjørck, Ditte Hartvig, Susanne Andresen, Berit Hulehøj Nielsen, Christina Hansen, Anne Nistrup, Keld Hundewadt, Niels Henrik Holländer

  718-727

• Changes in perfusion and permeability in glioblastoma model induced by the anti-angiogenic agents cediranib and thalidomide

  Jérôme Conq, Nicolas Joudiou, Véronique Préat, Bernard Gallez

  689-700

• Radiation-associated cutaneous mastocytosis: a case report and review of the literature

  Aaron Trando, Karen M. Austin, Brian Hinds, Ah-Reum Jeong, Aaron M. Goodman

  685-688
• 

  18F-FDG-PET/CT in breast cancer imaging: Restaging and Implications for treatment decisions in a clinical practice setting

  Ida Skarping

  669-677

• Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab

  Yana Beulque, Lisa Kinget, Eduard Roussel, Sajedeh Mobaraki, Annouschka Laenen, Philip R. Debruyne, Yannick Van Herck, Marcella Baldewijns, Agnieszka Wozniak, Abhishek D. Garg, Jessica Zucman-Rossi, Gabrielle Couchy, Maarten Albersen, Liesbeth De Wever, Lorenz Haaker, Benoit Beuselinck

  658-668

• Blood biomarkers for neuroaxonal injury and astrocytic activation in chemotherapy-induced peripheral neuropathy

  Jamila Adra, Daniel Giglio, Per Karlsson, Henrik Zetterberg, Zakaria Einbeigi

  636-641

• Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study

  Mirosława Püsküllüoğlu, Aleksandra Konieczna, Katarzyna Świderska, Joanna Streb, Małgorzata Pieniążek, Aleksandra Grela-Wojewoda, Renata Pacholczak-Madej, Anna Mucha-Małecka, Jerzy W. Mituś, Joanna Szpor, Michał Kunkiel, Agnieszka Rudzińska, Michał Jarząb, Marek Ziobro

  620-635

• Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis

  Delphine Schampers, Alexander Decruyenaere, Celine Jacobs, Lore Lapeire

  607-611

• The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy – the TABANETOC trial: study protocol for a randomized clinical multicenter trial

  Anna Karlsson, Gabriel Lindahl, Anna-Clara Spetz Holm, Karin Bergmark, Pernilla Dahm Kähler, Boglarka Fekete , Ulrika Ottander, Charlotte Öfverman, Pernilla Israelsson, Laila Falknäs, Anders Rosenmüller, Malena Tiefenthal Thrane, Shefqet Halili , Tomas L. Lindahl, Maria C. Jenmalm, Preben Kjølhede

  581-585

• 177Lu-PSMA radioligand therapy for isolated bilateral adrenal metastases from prostate cancer

  Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Kornelia Konz, Richard P. Baum

  557-562

• Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

  Helena Fohlin, Anna Nordenskjöld, Johan Rosell, Mårten Fernö, Tommy Fornander, Lisa Rydén, Lambert Skoog, Bo Nordenskjöld, Olle Stål

  535-541

• Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 – merging clinical research and standard healthcare

  Elisa Bjørgo, Gro L. Fagereng, Hege G. Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland

  487-490

• Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial

  Beatrice Mainoli, Joana Assis, José Dinis, Rui Henrique, Júlio Oliveira

  482-486

• Comparison of the use of a clinically implemented deep learning segmentation model with the simulated study setting for breast cancer patients receiving radiotherapy

  Nienke Bakx, Maurice van der Sangen, Jacqueline Theuws, Johanna Bluemink, Coen Hurkmans

  477-481

• Robust optimization of the Gross Tumor Volume compared to conventional Planning Target Volume-based planning in photon Stereotactic Body Radiation Therapy of lung tumors

  Thomas L. Fink, Charlotte Kristiansen, Torben S. Hansen, Torben F. Hansen, Rune S. Thing

  448-455